key: cord-0848713-bl3dub0r
authors: Thuluvath, Paul J.; Robarts, Polly; Chauhan, Mahak
title: Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases
date: 2021-08-26
journal: J Hepatol
DOI: 10.1016/j.jhep.2021.08.008
sha: a4de308a7b4a3f816e973a1411666182f1b5c00a
doc_id: 848713
cord_uid: bl3dub0r

BACKGROUND &AIMS: Liver transplant (LT) recipients or other immunocompromised patients were not included in the registration trials of vaccine studies against SARS-CoV-2. Although clinical efficacy of COVID vaccines in immunocompromised patients was unknown, many societies had recommended vaccination of this highly vulnerable patient population. METHODS: In this prospective study, we determined antibody (Ab) response to spike protein, 4 weeks after the 2(nd) dose of mRNA vaccines or after the single dose of Johnson & Johnson vaccine, in LT recipients and those with chronic liver diseases (CLD) with and without cirrhosis. RESULTS: Of the 233 patients enrolled so far, 62 had LT, 79 had cirrhosis (10 decompensated) and 92 had CLD without cirrhosis. Ab titers were defined as undetectable (<0.40 U/mL), suboptimal (0.40 - 250 U/mL) and adequate (>250 U/mL). Of the 62 patients who had LT, Ab levels were undetectable in 11 patients and suboptimal (median titer 17.6, range 0.47 - 212 U/mL) in 27 patients. Among 79 patients with cirrhosis, 3 had undetectable Ab and 15 had suboptimal (median titer 41.3, range 0.49 - 221 U/L) response. Of the 92 patients without cirrhosis, four had undetectable Ab and 19 had suboptimal (median titer 95.5, range 4.9 - 234 U/L) Ab response. Liver transplantation, use of 2 or more immunosuppression medications and vaccination with a single dose of Johnson & Johnson vaccine were associated with poor immune response on multivariable analysis. No patient had any serious adverse events. CONCLUSIONS: Poor antibody response after SARS-CoV-2 vaccination was seen in 61% of LT recipients and 24% of those with CLD. LAY SUMMARY: The clinical efficacy of COVID vaccines in immunocompromised patients is unknown. We did a prospective study to evaluate immune responses to COVID vaccines (Moderna, Pfizer or Johnson & Johnson) in 62 liver transplant recipients, 79 subjects with cirrhosis and 92 subjects with chronic liver diseases without cirrhosis. We found that 17.8% of liver transplant recipients, 3.8% of those with cirrhosis and 4.3% of those with chronic liver diseases without cirrhosis had undetectable antibody levels. In total, 61.3% of liver transplant recipients and 24% of those with chronic liver diseases (with or without cirrhosis) had poor antibody response (undetectable or suboptimal). Liver transplantation, use of immunosuppressive medications and vaccination with a single dose of Johnson & Johnson vaccine were associated with poor antibody response when adjusted for other factors.

Patients with chronic liver disease and cirrhosis have worse outcomes from COVID-19 compared to those without liver disease. [1] [2] [3] Therefore, liver societies have recommended SARS-CoV-2 vaccination of all patients with chronic liver diseases. Although the data on the outcomes of liver transplant recipients with COVID-19 are inconsistent, there is a definite trend towards higher mortality risks in transplant recipients. 4, 5 Liver transplant recipients or other immunocompromised patients were not included in the registration trials of mRNA vaccine studies for SARS-CoV-2. Although clinical efficacy of COVID vaccine in immunocompromised patients was unknown, many societies had recommended vaccination of this highly vulnerable patient population. [6] [7] [8] [9] It has been suggested, based on circumstantial evidence, that it is prudent to vaccinate immunocompromised subjects since the benefits outweigh the risks. [10] [11] However, a recent study reported that only 17% of organ transplant recipients developed detectable antibody to SARS-CoV-2 spike protein after the first dose of mRNA vaccines. 12 Lower immune response was anticipated since humoral immunity is critical for antibody response after the vaccination, but the response seen after the first dose was disappointingly low.

We hypothesized that liver transplant recipients and those with advanced liver disease will have suboptimal response to SARS-CoV-2 vaccines. To test this hypothesis, in this ongoing prospective study, we assessed antibody responses 4 weeks after the 2 nd dose of mRNA vaccines or after the single dose of Johnson & Johnson vaccine in liver transplant recipients and in those with chronic liver diseases with or without cirrhosis.

In this prospective study, all adult patients (>18 years) with established chronic liver disease or those who received liver transplantation were eligible for the study. The exclusion J o u r n a l P r e -p r o o f criteria were untreated or uncontrolled HIV (human immune deficiency virus) infection, previous exposure to COVID-19 or those who did not complete a standardized vaccination protocol (4 weeks between Moderna doses and 3 weeks between Pfizer doses) as per the manufacturer of the vaccine.

We collected clinical characteristics (age, sex, race, body mass index), etiology of liver disease, comorbidities (diabetes, hypertension, chronic obstructive pulmonary disease, heart failure, inflammatory bowel disease, chronic kidney disease, malignancy, smoking history and ongoing alcoholism) and concomitant medications of all patients who were eligible for mRNA or Johnson & Johnson vaccine by age, comorbidities or employment criteria. Presence or absence of cirrhosis was confirmed in all cases using clinical or biochemical evidence (splenomegaly, ascites, hepatic encephalopathy), Fibroscan, liver imaging, endoscopy or liver biopsy. If patient had previous SARS-CoV-2 tests (RT-PCR, antigen or antibody tests), those were recorded, but they were excluded from the study if the tests were positive.

Dates of vaccination and the types of vaccine were confirmed in all patients. All potential side effects after the 1 st and 2 nd dose were collected. Following adverse events were collected: local injection site reaction including pain, swelling, redness, axillary swelling and tenderness on vaccination arm, and systemic reactions including fatigue, headache, muscle pain, chills, joint pain, fever, and nausea/vomiting. Data were entered into an excel database in a de-identified mode by giving them a coded number. All data were saved in a password-protected format and filed in the GI Research share drive and only the study staff had access to the file to download for any study procedures or audit. The data will continue to be stored indefinitely in a confidential manner in a secured hospital shared drive according to the 21 CFR part 11 guidelines.

Our plan is to continue to follow our patients for 1-year to understand the differential attrition of antibody levels with time and also to assess the laboratory confirmed COVID-19 infection in vaccinated patients.

Antibody testing: Patients were tested for SARS-CoV-2 protein by Roche semi-quantitative assay (Elecsys ® Ant-SARS-CoV2 semi-quantitative) via LabCorp. 13 The test has reported 99.98% negative and 96.6% positive percent agreement to detect antibodies to SAR-CoV-2 spike protein 15 days (as per the laboratory website) after the diagnosis of COVID-19 by a PCR test. 13 The accuracy of this test has also been confirmed in comparative studies. 14 The LabCorp uses > 250 U/mL as evidence of immune response and <0.4 U/mL as undetectable.

Statistical analysis: Patients were stratified into three groups based on antibody levels (U/mL): < 0.4 (undetectable), 0.4 -249 (suboptimal), and > 250 (optimal). Chi-square test was used to calculate the differences among these three groups. To identify independent variables that were associated with poor antibody response, the undetectable and suboptimal group were combined as one group. Variables that were significant (p <0.05) in simple logistic regression model were included in the multiple logistic regression model.

The study was approved by the institutional review board (IRB, MMC# 2021-02). Informed consent was obtained verbally and the IRB reviewed and approved the verbal consent process that was recorded in the electronic medical records. Figure   1A ). As could be seen in table 1, most patients had multiple comorbidities.

Of the 62 patients who had liver transplantation, antibody levels were detectable at very low levels (median 17.6, range 0.47 -212 U/mL) in 27 patients and were undetectable (<0.4 U/mL) in 11 (17.8%) patients (Table 1) . Only 24 (39.0%) had antibody levels above 250 U/mL.

Of the 11 patients with undetectable antibody, one patient was on 3 drugs including prednisone, Figure 3B ). Although there was a trend, treatment with a single immunosuppressive medication was not significant on multiple logistic regression analysis.

None of the patients who received the vaccine had any serious adverse events. The common side effects (> 5%) after the 1 st dose were local pain at the injection site (53%) and fatigue (16%). After the 2 nd dose, the side effects were local pain at the injection site (49%), fatigue (23%), fever (8%), chills (6%), headache (7%) and myalgia (6%) (Supplementary table 2), As reported previously in healthy subjects, the side effects were more common after the 2 nd dose of MRNA vaccines.

In this study, 61% of patients who had liver transplant and 24% with chronic liver diseases had poor Ab responses. After adjusting for other variables, treatment with 2 or more Although we measured antibody to spike protein in this study, it has been shown to correlate very well with neutralizing antibodies. 15 Our findings are based on a relatively small sample size, but the clinicians should be aware of these observations and provide appropriate guidance regarding continued social distancing to immunocompromised patients including those Based on our preliminary data, we would discourage single dose vaccines in immunocompromised subjects. Although Moderna vaccine showed a better response than Pfizer vaccine (76.4% vs. 64.4%), it is premature to comment on it based on a non-randomized study.

Our observations suggest that most immunocompromised patients, irrespective of the cause, may not mount adequate antibody responses in a consistent manner. The degree of immunosuppression may also be important since being on one immunosuppressive medication was not independently associated with a poor response. Since this study focused specifically on J o u r n a l P r e -p r o o f liver transplant recipients and those with chronic liver diseases, we cannot comment on other immunosuppressed patients. Most of our patients who did not respond well had multiple comorbidities, but these same patients are also at a higher risk of death if they were to develop COVID-19. Comorbidities were not associated with poor Ab responses, but our observations will need further corroboration in larger studies.

We have previously reported inadequate immune responses in patients with cirrhosis who Figure 1A : Undetectable, suboptimal and optimal antibody response rates in CLD without cirrhosis, cirrhosis and liver transplantation, Figure 1B : Undetectable, suboptimal and optimal antibody response rates in those who received Johnson & Johnson, Moderna and Pfizer vaccines. Figure 1C : Undetectable, suboptimal and optimal antibody response rates in those who are on 0, 1, 2-3 immunosuppressive medications.

J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f Human immunodeficiency virus 2 (1) 0 (0) 2 (3) 0 (0) BMI -body mass index; CC-compensated cirrhosis; DC-decompensated cirrhosis; NAFLDnon-alcoholic fatty liver disease; SD-standard deviation. *Others: Hispanic and Asians. **Other liver disease: hepatocellular carcinoma, hemochromatosis. ***Other medications: cyclosporine, mycophenolic acid, sirolimus and tyrosine kinase inhibitor. #Numbers may not add up since some had more than one risk factor NAFLD -non-alcoholic fatty liver disease; PBC-primary biliary cholangitis; PSCprimary sclerosing cholangitis; SD: standard deviation. # When there was more than one etiology, classified by predominant cause for statistical analysis Etiology of liver disease, presence of cirrhosis and renal impairment were not significant in multiple logistic regression analysis J o u r n a l P r e -p r o o f

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study

Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis

Elevated Liver Biochemistries in Hospitalized Chinese Patients with Severe COVID-19: Systematic Review and Metaanalysis

ELITA-ELTR COVID-19 Registry. Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: Results from the ELITA/ELTR Multi-center European Study

Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study

EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients

An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology

Online ahead of print

Korean College of Rheumatology Task Force for COVID-19 Vaccine Guidance for Patients with

Autoimmune Inflammatory Rheumatic Diseases

COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI)

SARS-CoV-2 vaccination in IBD: more pros than cons

Covid-19 vaccination in immunocompromised

Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients

Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation